Circular noncoding RNAs as potential therapies and circulating biomarkers for cardiovascular diseases review-article

Ahmed S. Bayoumi, Tatsuya Aonuma, Jian Peng Teoh, Yao Liang Tang, Il-man Kim

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Recent advancements in genome-wide analyses and RNA-sequencing technologies led to the discovery of small noncoding RNAs, such as microRNAs (miRs), as well as both linear long noncoding RNAs (lncRNAs) and circular long noncoding RNAs (circRNAs). The importance of miRs and lncRNAs in the treatment, prognosis and diagnosis of cardiovascular diseases (CVDs) has been extensively reported. We also previously reviewed their implications in therapies and as biomarkers for CVDs. More recently, circRNAs have also emerged as important regulators in CVDs. CircRNAs are circular genome products that are generated by back splicing of specific regions of pre-messenger RNAs (pre-mRNAs). Growing interest in circRNAs led to the discovery of a wide array of their pathophysiological functions. CircRNAs have been shown to be key regulators of CVDs such as myocardial infarction, atherosclerosis, cardiomyopathy and cardiac fibrosis. Accordingly, circRNAs have been recently proposed as potential therapeutic targets and biomarkers for CVDs. In this review, we summarize the current state of the literature on circRNAs, starting with their biogenesis and global mechanisms of actions. We then provide a synopsis of their involvement in various CVDs. Lastly, we emphasize the great potential of circRNAs as biomarkers for the early detection of CVDs, and discuss several patents and recent papers that highlight the utilization of circRNAs as promising biomarkers.

Original languageEnglish (US)
Pages (from-to)1100-1109
Number of pages10
JournalActa Pharmacologica Sinica
Volume39
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Long Noncoding RNA
Untranslated RNA
Cardiovascular Diseases
Biomarkers
Therapeutics
MicroRNAs
Genome
RNA Sequence Analysis
circular RNA
Small Untranslated RNA
Patents
Cardiomyopathies
Early Diagnosis
Atherosclerosis
Fibrosis
Myocardial Infarction
Technology

Keywords

  • RNAs
  • atherosclerosis
  • biomarkers
  • cardiac fibrosis
  • cardiomyopathy
  • circular RNAs
  • heart failure
  • myocardial infarction
  • noncoding

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Circular noncoding RNAs as potential therapies and circulating biomarkers for cardiovascular diseases review-article. / Bayoumi, Ahmed S.; Aonuma, Tatsuya; Teoh, Jian Peng; Tang, Yao Liang; Kim, Il-man.

In: Acta Pharmacologica Sinica, Vol. 39, No. 7, 01.07.2018, p. 1100-1109.

Research output: Contribution to journalReview article

Bayoumi, Ahmed S. ; Aonuma, Tatsuya ; Teoh, Jian Peng ; Tang, Yao Liang ; Kim, Il-man. / Circular noncoding RNAs as potential therapies and circulating biomarkers for cardiovascular diseases review-article. In: Acta Pharmacologica Sinica. 2018 ; Vol. 39, No. 7. pp. 1100-1109.
@article{6a1e6f383dd64b04af7fd51fc72e5306,
title = "Circular noncoding RNAs as potential therapies and circulating biomarkers for cardiovascular diseases review-article",
abstract = "Recent advancements in genome-wide analyses and RNA-sequencing technologies led to the discovery of small noncoding RNAs, such as microRNAs (miRs), as well as both linear long noncoding RNAs (lncRNAs) and circular long noncoding RNAs (circRNAs). The importance of miRs and lncRNAs in the treatment, prognosis and diagnosis of cardiovascular diseases (CVDs) has been extensively reported. We also previously reviewed their implications in therapies and as biomarkers for CVDs. More recently, circRNAs have also emerged as important regulators in CVDs. CircRNAs are circular genome products that are generated by back splicing of specific regions of pre-messenger RNAs (pre-mRNAs). Growing interest in circRNAs led to the discovery of a wide array of their pathophysiological functions. CircRNAs have been shown to be key regulators of CVDs such as myocardial infarction, atherosclerosis, cardiomyopathy and cardiac fibrosis. Accordingly, circRNAs have been recently proposed as potential therapeutic targets and biomarkers for CVDs. In this review, we summarize the current state of the literature on circRNAs, starting with their biogenesis and global mechanisms of actions. We then provide a synopsis of their involvement in various CVDs. Lastly, we emphasize the great potential of circRNAs as biomarkers for the early detection of CVDs, and discuss several patents and recent papers that highlight the utilization of circRNAs as promising biomarkers.",
keywords = "RNAs, atherosclerosis, biomarkers, cardiac fibrosis, cardiomyopathy, circular RNAs, heart failure, myocardial infarction, noncoding",
author = "Bayoumi, {Ahmed S.} and Tatsuya Aonuma and Teoh, {Jian Peng} and Tang, {Yao Liang} and Il-man Kim",
year = "2018",
month = "7",
day = "1",
doi = "10.1038/aps.2017.196",
language = "English (US)",
volume = "39",
pages = "1100--1109",
journal = "Zhongguo yao li xue bao = Acta pharmacologica Sinica",
issn = "1671-4083",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Circular noncoding RNAs as potential therapies and circulating biomarkers for cardiovascular diseases review-article

AU - Bayoumi, Ahmed S.

AU - Aonuma, Tatsuya

AU - Teoh, Jian Peng

AU - Tang, Yao Liang

AU - Kim, Il-man

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Recent advancements in genome-wide analyses and RNA-sequencing technologies led to the discovery of small noncoding RNAs, such as microRNAs (miRs), as well as both linear long noncoding RNAs (lncRNAs) and circular long noncoding RNAs (circRNAs). The importance of miRs and lncRNAs in the treatment, prognosis and diagnosis of cardiovascular diseases (CVDs) has been extensively reported. We also previously reviewed their implications in therapies and as biomarkers for CVDs. More recently, circRNAs have also emerged as important regulators in CVDs. CircRNAs are circular genome products that are generated by back splicing of specific regions of pre-messenger RNAs (pre-mRNAs). Growing interest in circRNAs led to the discovery of a wide array of their pathophysiological functions. CircRNAs have been shown to be key regulators of CVDs such as myocardial infarction, atherosclerosis, cardiomyopathy and cardiac fibrosis. Accordingly, circRNAs have been recently proposed as potential therapeutic targets and biomarkers for CVDs. In this review, we summarize the current state of the literature on circRNAs, starting with their biogenesis and global mechanisms of actions. We then provide a synopsis of their involvement in various CVDs. Lastly, we emphasize the great potential of circRNAs as biomarkers for the early detection of CVDs, and discuss several patents and recent papers that highlight the utilization of circRNAs as promising biomarkers.

AB - Recent advancements in genome-wide analyses and RNA-sequencing technologies led to the discovery of small noncoding RNAs, such as microRNAs (miRs), as well as both linear long noncoding RNAs (lncRNAs) and circular long noncoding RNAs (circRNAs). The importance of miRs and lncRNAs in the treatment, prognosis and diagnosis of cardiovascular diseases (CVDs) has been extensively reported. We also previously reviewed their implications in therapies and as biomarkers for CVDs. More recently, circRNAs have also emerged as important regulators in CVDs. CircRNAs are circular genome products that are generated by back splicing of specific regions of pre-messenger RNAs (pre-mRNAs). Growing interest in circRNAs led to the discovery of a wide array of their pathophysiological functions. CircRNAs have been shown to be key regulators of CVDs such as myocardial infarction, atherosclerosis, cardiomyopathy and cardiac fibrosis. Accordingly, circRNAs have been recently proposed as potential therapeutic targets and biomarkers for CVDs. In this review, we summarize the current state of the literature on circRNAs, starting with their biogenesis and global mechanisms of actions. We then provide a synopsis of their involvement in various CVDs. Lastly, we emphasize the great potential of circRNAs as biomarkers for the early detection of CVDs, and discuss several patents and recent papers that highlight the utilization of circRNAs as promising biomarkers.

KW - RNAs

KW - atherosclerosis

KW - biomarkers

KW - cardiac fibrosis

KW - cardiomyopathy

KW - circular RNAs

KW - heart failure

KW - myocardial infarction

KW - noncoding

UR - http://www.scopus.com/inward/record.url?scp=85048963552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048963552&partnerID=8YFLogxK

U2 - 10.1038/aps.2017.196

DO - 10.1038/aps.2017.196

M3 - Review article

C2 - 29565037

AN - SCOPUS:85048963552

VL - 39

SP - 1100

EP - 1109

JO - Zhongguo yao li xue bao = Acta pharmacologica Sinica

JF - Zhongguo yao li xue bao = Acta pharmacologica Sinica

SN - 1671-4083

IS - 7

ER -